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Short Title: Varicella Zoster Virus in the immunosuppressed  
 
 
Abstract 
Chickenpox and shingles can be more severe and occasionally life threatening in immunosuppressed 
patients. As such, some groups warrant a more detailed history, serological testing and 
consideration of prophylaxis following contact with the virus. Active disease may also require more 
aggressive treatment with antivirals. Guidance for the use of Varicella Zoster Immunoglobulin (VZIG) 
has recently been updated by Public Health England with important implications for rheumatology 
patients. 
 
Key Words: Varicella Zoster Virus, VZV, varicella, chickenpox, zoster, shingles, immunosuppressed, 
varicella zoster immunoglobulin, VZIG, contact, infection, aciclovir, antiviral, vaccine 
 
Key messages 
Immunosuppressed patients should be assessed for prophylaxis following contact with Varicella 
Zoster Virus. 
Some patients should have serological testing following contact even if they have a past history 
of chickenpox. 
The chickenpox and shingles vaccines are live and should be avoided in some 
immunosuppressed groups. 
 
Introduction 
Varicella Zoster Virus (VZV) is one of eight herpesviruses that are known to cause disease in humans. 
Primary infection occurs as chickenpox, also known as varicella, with fever and widespread rash. In 
otherwise well children, it is self-limiting and rarely life threatening, although encephalitis and 
pneumonitis can complicate the disease. Primary infection in adults, whilst much less common, is 
more frequently associated with complications and has a 25-fold increased mortality compared to 
children [1]. Following primary infection, the virus lies dormant in the nervous system and can 
reactivate later in life as shingles, also known as zoster. Shingles may be complicated by chronic pain 
(post herpetic neuralgia) in the region affected, which occurs more frequently in older individuals 
[2]. Rarely, shingles can extend across multiple dermatomes, or even disseminate systemically. Some 
forms of immunosuppression increase the risk of both severe primary infection in people without 
prior exposure to the virus, and dissemination of infection following reactivation. This review will 
discuss the assessment and management of immunosuppressed adults with rheumatic disease who 
are at risk of VZV infection or reactivation. 
 
Methodology 
Publications included in this review were identified using computerised searches of the following 
databases: MEDLINE, EMBASE and CENTRAL. Search terms included combinations of Varicella Zoster 
Virus, VZV, chickenpox, shingles, immunosupp*, immunocomprom*, vaccin* VZIG, 
aciclovir/acyclovir, antiviral*, treatment, prevention with individual names of rheumatic conditions 
and treatments. Guidelines from Public Health England, Centre for Disease Control and other 
organisations were reviewed. 
 
CASE SCENARIO 
A 36 year-old woman, Mrs L is being treated with cyclophosphamide infusions and prednisolone 
40mg daily for a small vessel vasculitis and asks for advice as her 3 year-old child has developed 
chickenpox. She believes she had chickenpox as a child. 
 
Pathogenesis 
There are nine genotype strains of VZV, although for clinical purposes, the virus is considered to be a 
single entity as cross-protection of immunity occurs. The virus is highly contagious with transmission 
starting one to two days prior to the onset of rash and continuing until all lesions have crusted over.  
Viral spread is from skin vesicles and respiratory droplets (Fig.1 from [3]). Primary VZV infection 
begins with replication in epithelial cells of the upper respiratory tract.  The innate immune system 
mediates the first response via natural killer (NK) cells and the cytokines interferon IFN-α and IFN-γ 
[4]. During an incubation period of 10-21 days the virus spreads to local lymphoid tissue, T cells [3] 
and then the skin culminating in the characteristic widespread vesicular rash of chickenpox [5].  The 
cellular immune system, including CD4+ T-cells, then clears the virus and prevents life-threatening 
dissemination [6, 7].  Antibody responses are less important in primary infection, although have a 
role in neutralising the virus upon re-exposure [8].  
During primary infection the virus establishes latency in dorsal root ganglia with later reactivation 
and anterograde transport to the skin causing the dermatomal eruption of shingles.  Varicella 
specific T-cells are important in preventing shingles and their decline in number with advancing age 
correlates with an increasing incidence of disease [9].  
Varicella DNA can be detected in blood from patients with shingles [10] and satellite lesions are an 
independent risk factor for severe disease [11].   A patient has disseminated zoster when twenty or 
more vesicles are present beyond the primary or adjacent dermatome [12], or in any patient with 
shingles and other organ involvement. 
   
Epidemiology of infection and immunity 
In the United Kingdom, where childhood vaccination against chickenpox is not routine, 77% of 
children experience the disease by the age of 5 [13].  By 16 years of age, 90% of the UK population 
will have serological evidence of exposure [14].  Infection may be subclinical and unrecognized by 
the individual: in adolescents with a negative or uncertain history of chickenpox, 67% and 84% show 
immunity respectively [15].   
 
When someone in a household develops chickenpox, over two thirds of susceptible contacts will also 
develop primary infection [16].  In contrast, household contact with shingles, which has a lower total 
cutaneous viral load, results in chickenpox in an estimated 8-15% of susceptible individuals [17].   
In the UK, the life time risk of shingles is 50% in those living to 85 years [18]. The adjusted risk 
increases with age and conditions including rheumatoid arthritis (RA) (table 1 from [19]). 
Immunosuppressive therapies may increase the risk and severity of chickenpox and shingles but 
establishing the degree of this risk for individual treatments is challenging.  First, susceptibility to 
shingles is increased (regardless of treatment) in those with autoimmune conditions including RA 
[19] and systemic lupus erythematosus (SLE) [20].  Second, chickenpox is rare in adults so available 
data is often limited to case reports or series with reporting and other biases. Third, incidence rates 
of shingles, although higher, are often not high enough to allow a meaningful comparison between 
groups in randomised controlled trials (RCTs).  Therefore, our understanding of risk is often limited 
to data from retrospective or observational studies and registries where multiple factors, including 
other immunosuppressive medications, can confound results.  
Nevertheless, the available evidence from the paediatric literature is strong for a temporal 
relationship between severe VZV infection and steroid use [21, 22].  In adults with RA, the adjusted 
hazard ratio (HR) for shingles in those taking prednisolone <7.5mg daily is estimated at 1.55 (95% CI 
1.25–1.93) and 2.35 (1.81–3.04) for >7.5mg daily [23].  In contrast, data are not convincing for an 
increased risk of shingles or chickenpox in adults taking methotrexate [24] (and reviewed in [25]).  A 
large prospective study of rheumatology patients in the U.S. found an increased risk of shingles in 
those taking cyclophosphamide (hazard ratio (HR) 4.2, 95% CI 1.6-11.5), azathioprine (HR 2 95% CI 
1.2-2.3) or leflunomide (HR 1.4 95% CI 1.1-1.8) [26]. Data from a small series of paediatric renal 
transplant recipients have raised concern over the role of mycophenolate mofetil (MMF) in 
disseminated VZV infection [27]. 
Biologic therapies have now become a mainstay of treatment in many rheumatic diseases.  A meta-
analysis of patients with RA from registry data found an increased risk for shingles with anti TNF 
treatment as a class with an estimated hazard ratio of 1.6 (95% CI 1.16-2.23) [28].  Some data 
suggest a lower risk for etanercept [26, 29, 30].  A large prospective cohort study found no additional 
risk of HZ in patients taking anti TNF compared to conventional DMARD therapy [31].  A recent 
meta-analysis of 18 RCTs also found no significant increased risk of shingles in those taking anti TNF 
therapy compared to controls although the number of cases of shingles in all groups was small and 
many RCTs excluded patients at highest risk for example those over 75 [32]. In summary, registry 
data support a modest increased risk of shingles with anti TNF treatment whilst RCT data do not.  
Data on other biologics are limited but two studies of patients with RA found no significant 
difference in adjusted hazard ratios of shingles in those taking abatacept, rituximab, tociluzimab and 
various anti TNF therapies [23, 33].  Preliminary data from phase II and III randomised controlled 
trials of the Janus Kinase (JAK) inhibitor tofacitinib in RA have shown an increased risk of 
uncomplicated zoster [34], recently estimated as double that of other biologics [35]. 
The specific effect of different immunosuppressive treatments on VZV humoral immunity is 
unknown. One study found that 17% of children lost detectable VZV IgG following chemotherapy for 
haematological and solid organ tumours [36]. Another found reduced cell mediated but not humoral 
immunity in adults with SLE and granulomatosis with polyangitis (GPA) on treatments including 
prednisolone, methotrexate, azathioprine and mycophenolate compared to healthy controls [37]. In 
an Israeli cross-sectional study of 104 adult patients with inflammatory bowel disease and a positive 
history of VZV infection or vaccination, 7 tested negative or equivocal for VZV IgG [38]. Of these, 6 
were using anti TNF therapy and one methotrexate monotherapy. 
The lifetime risk of contact with VZV in adult immunosuppressed rheumatology patients is also 
unknown but is likely to be significant given the typical longevity of treatment and particularly in 
those who have frequent contact with young children.  Most immunosuppressed adult patients who 
come into contact with VZV have prior immunity but it is important to identify and consider 
treatment in those who do not, following significant exposure.  
 
Assessment of VZV exposure and risk 
Public health England (PHE) define significant exposure in the UK Immunisation Against Infectious 
Disease guide (also known as the Green Book) [39] as household contact, face-to-face contact (e.g. 
having a conversation), being in the same room for 15 minutes or the same 2 to 4 bed hospital bay 
with someone with chickenpox or exposed  (e.g. ophthalmic) zoster.  In general, non-household 
contact with someone with covered shingles is not considered significant unless the person with 
shingles is themselves immunosuppressed and therefore considered to shed more virus.  Contact 
with a well person within the two days prior to the onset of their chickenpox rash should also be 
considered significant if the above criteria are met. 
Recent guidance from PHE [40] on the issuing of VZIG, divides immunosuppressed individuals into 
groups according to the nature of the immunosuppressive therapy. An interpretation of this division 
relevant to patients with rheumatic conditions is given in table 2 and the associated treatment 
algorithm (fig 2).  
Public Health England advise that no further action is required following contact with VZV for 
patients in the low risk group. This is based on the assumed low risk of severe disease posed by 
these medications and the high likelihood of prior immunity even with a negative history of 
chickenpox.  However, PHE also advise that aciclovir prophylaxis may be considered after discussion 
with the specialist physician caring for the patient.  Some patients within this group will be at a 
higher risk than others so it may be prudent to establish a history of prior infection, vaccination or 
serology in, for example, someone on both prednisolone 20mg daily and azathioprine 3mg/kg 
despite them being in the lowest risk group.  
If patients in the intermediate risk group A have a history of chickenpox, shingles, previous 
varicella/zoster vaccination or previous serological evidence of immunity, then no further immediate 
action is needed following contact with VZV. If not then serostatus should be established and VZIG) 
offered if seronegative (see next section). If testing were to delay treatment beyond 7 days post 
contact then the patient’s age needs to be considered. Those over 50 are considered more likely to 
be immune so delaying treatment is acceptable; for those under 50, treatment should not be 
delayed beyond 7 days post contact whilst awaiting serological results.  If a delay does occur then 
VZIG should still be considered up to 14 days post exposure when it is still potentially protective. 
Individuals in the high risk group B include those on cyclophosphamide, cyclosporin, leflunomide, 
monoclonal antibodies or cytokine inhibitors.  Following contact, patients in this group should have 
their serostatus rechecked regardless of a history of prior infection, vaccination or previous positive 
serology. The rationale being that immunosuppressive treatments in this group may deplete VZV 
specific antibody titres to non-protective levels. This recommendation is based on expert opinion as 
the impact of specific immunosuppressive regimens on VZV specific humoral and cellular immunity is 
largely unknown (see epidemiology section). Further, it is debatable whether some treatments 
including leflunomide should be included in this group on the available evidence [26]. 
Serological testing for VZV IgG is relatively low cost and results can be generally available within 24 
hours. Varicella specific IgG will be detectable in most patients who have had chickenpox, shingles or 
received the varicella or shingles vaccine. However, commercial assays are less sensitive for 
detecting vaccine-induced immunity [41]. Serological assays may detect IgG in those who have 
recently received antibody containing blood products, such as human normal immunoglobulin (IVIG) 
[42], or after blood transfusion [43] –these are false positive with respect to identifying a past 
history of infection but are likely to reflect equivalent passive protection afforded by use of VZIG.   
If a patient has existing immunity then no specific action is required following contact with VZV; 
however reports do exist of disseminated infection following exposure in this setting [44] and so 
patients should still be advised to urgently report early signs of infection.  
 
Management of varicella exposure 
Following significant contact with VZV, prophylaxis can be offered in two forms: antiviral agents (e.g. 
aciclovir or valaciclovir) and varicella zoster immunoglobulin (VZIG).  There have been no RCTs 
directly comparing these modalities. 
VZIG is prepared from pooled plasma of donors with suitably high titres of VZ antibody.  The similar, 
but no longer available, zoster immune globulin (ZIG) was demonstrated to prevent chickenpox in 
healthy children when given within 72 hours of household exposure[45]. In immunocompromised 
children, ZIG [46, 47] and VZIG [48] reduce the incidence of chickenpox and modify disease severity 
compared to historical controls. The duration of protection that is provided after VZIG 
administration is unknown but is likely to broadly equate to the half-life of other immunoglobulins of 
3-4 weeks [49].  Approximately half of susceptible household contacts will develop chickenpox 
despite receiving VZIG [50]. This group will generally have attenuated disease but should still be 
considered for antiviral therapy if a chickenpox like illness develops.   
 
VZIG is given as an intramuscular (IM) injection. In patients for whom IM injections are 
contraindicated, for example those with clotting disorders or severe thrombocytopenia, IVIG (which 
will contain some VZV specific antibody) can be used [39].  In patients receiving regular (e.g. 
monthly) IVIG for gammaglobulin deficiencies, VZIG need not be used [39]. In patients taking 
warfarin, small volume IM injections (e.g. influenza vaccine) appear to be safe [51, 52]; it is not 
known if larger volume injections such as VZIG carry a significant risk.  Options therefore include 
splitting the dose between different sites or giving it subcutaneously as per manufacturer guidance 
[49] although evidence of clinical efficacy via this route is lacking.  Data regarding newer oral 
anticoagulants are also lacking. 
If VZIG and IVIG are unavailable, contraindicated or a patient prefers not to receive a blood-derived 
product,  aciclovir can be used prophylactically at a dose of 10mg/kg 4 times a day for 7 days, 
starting 1 week after exposure [40, 53].  Aciclovir prevents the development of chickenpox following 
close contact in healthy, susceptible children but there is some concern that it may attenuate long 
term immunity [54]. One small study has suggested added benefit of aciclovir with VZIG compared 
to VZIG alone in children with renal disease taking steroids [55].   
In patients who meet criteria for receiving VZIG, it is reasonable to withhold biologic therapy until 
the incubation period of 21 days has passed.  This is in keeping with manufacturer guidance for 
Etanercept.  Sulfasalazine and hydroxychloroquine are generally considered to be of low risk in this 
setting but decisions to withhold other non-biologic DMARDs must be assessed on an individual 
basis. It is noteworthy that there is an increased risk of neurotoxicity if ciclosporin is co-administered 
with aciclovir or valaciclovir [56] .  Aciclovir is excreted by the same renal tubular system as 
mycophenolate mofefil but co-administration does not result in clinically significant change in drug 
levels in patients with normal renal function [57]. 
 
Primary prevention 
A single dose, live attenuated chickenpox vaccine was licensed and recommended for routine use in 
children in the U.S. in 1995.  The schedule was changed in 2005 to two doses given at least four 
weeks apart following evidence that this regimen provides 98% protection against clinical disease in 
children over a period of 10 years, compared to 94% following a single dose [58].  Seroconversion 
rates in healthy adolescents and adults are approximately 75% and 99% after one or two doses 
respectively [59].   
In the UK, the chickenpox vaccine is currently recommended only for non-immune healthcare 
workers and for non-immune close contacts of more severely immunocompromised patients [60] 
such as those receiving chemotherapy. This approach could be extended, for example, to a non-
immune child of a mother receiving cyclophosphamide and high dose steroids for a rheumatological 
condition. 
The chickenpox vaccine is associated with a mild vesicular rash in 8% of healthy seronegative adults 
[61]. Concern over vaccine-strain disease has led PHE to advise against the use of the vaccine in 
immunosuppressed patients [39].  A recent study found that when given to 31 non-immune children 
receiving active chemotherapy for haematological or solid organ malignancy, the vaccine caused 
only a mild vesicular rash in 7 [62]. The risk of vaccination in seronegative, immunosuppressed adults 
is unknown. The Centre for Disease Control (CDC) advise avoidance in those who are severely 
immunosuppressed including those taking more than 20mg of prednisolone daily for more than two 
weeks.  Guidance from EULAR states the vaccine can be used in those mildly immunosuppressed, 
but without defining this group [63].  
Public Health England do allow for the use of the more potent, live zoster vaccine in those taking 
long term prednisolone <20mg per day and/or methotrexate <25mg per week or azathioprine 
<3mg/kg/day [64]. This may seem paradoxical given the zoster vaccine contains 14 times more virus 
than the chickenpox vaccine but this might reflect that the guidance for the latter was written with 
more heavily immunosuppressed paediatric patients in mind. Further, it is generally assumed that 
patients receiving the zoster vaccine will have prior immunity and therefore be at lower risk of 
vaccine strain disease.  Despite this, PHE do not explicitly prohibit its use in immunosuppressed 
patients who are seronegative. In contrast, EULAR do recommend avoiding the zoster vaccine in this 
group [63] .  The CDC do not require prior immunity to be established and state the vaccine may be 
considered even in patients on biologic therapy on a case by case basis [65].  If a decision is made to 
vaccinate a patient known to be seronegative, then expert opinion suggests the lower potency 
chickenpox vaccine should be used [66].  There are case reports of fatal vaccine strain disease 
following inadvertent zoster vaccination in patients who are heavily immunosuppressed [67].  
However a recent retrospective study in the U.S. found no cases of serious vaccine strain disease in 
4826 patients receiving various immunosuppressive medications including high dose steroids (550 
patients), methotrexate (683), azathioprine (164), leflunomide (126) and etanercept (130) [68].  It is 
not known how many of these patients had prior immunity but in keeping with the rest of the U.S. 
population it is likely to be in the region of 99%, compared to 90% in the UK [14, 69]. A randomised 
controlled pilot study assessing the safety and effectiveness of the live zoster vaccine in patients on 
anti-TNF therapy is currently recruiting [70].  
If an adult immunosuppressed patient does develop a vesicular rash following vaccination, viral 
swabs should be sent for genomic analysis to distinguish vaccine strain from wild-type virus.(see 
[71]).  
An inactive, herpes zoster subunit vaccine, given intramuscularly 2 months apart, has recently been 
trialled in healthy, non-immunosuppressed adults. In those over 50, the vaccine is 97% effective in 
preventing HZ over a mean follow up of 3.2 years [72].  In patients over 70 the vaccine is 90% 
effective over 3.7 years with a similar reduction in post herpetic neuralgia [73].   Immunosuppressed 
patients were excluded from both studies. 
An alternative, heat inactivated VZV vaccine, given as four separate doses 30 days apart reduces the 
incidence of zoster in patients receiving bone marrow transplantation for lymphoma [74]. The 
vaccine is immunogenic in various immunosuppressed groups [75] and a large placebo controlled, 
phase III trial assessing clinical efficacy in these groups is due to publish soon [76].  
If a non-live vaccine becomes available and is effective in immunosuppressed patients, it will remove 
much of the uncertainty described above and may play an important role in both primary prevention 
and post-exposure prophylaxis. Until then, the live varicella vaccine may be considered prior to 
immunosuppression in some groups who have no history of chickenpox, shingles or vaccination and 
are found to be seronegative.   However, following PHE guidance, this would necessitate a delay in 
treatment of at least 2 or 6 weeks if a single or double dose regimen is used respectively.  
 
Treatment of active disease  
Aciclovir reduces the severity of chickenpox in healthy children [77] and also in adults when given 
within 24 hours of disease onset [78] [79]. The British Infection Society recommends treatment of 
chickenpox in immunocompetent adults (without complications) with oral antivirals within 24-48 
hours of rash onset [80].  Immunosuppressed patients should receive IV aciclovir 10mg/kg three 
times daily (if eGFR is above 50). The society defines immunosuppressed as including patients in the 
equivalent of PHE groups A and B (see above) but also those taking methotrexate or azathioprine. It 
was issued before much of the reassuring safety data regarding methotrexate was published [24].  
In the context of shingles, aciclovir administered within 48-72 hours of rash onset significantly 
reduces the incidence of acute neuritis in healthy adults [81] although there may not be any 
associated reduction in chronic post herpetic neuralgia [82]. Valaciclovir is an alternative antiviral 
agent with a longer, more convenient dosing interval and it may be more effective than aciclovir in 
treating shingles [83]. In the immunosuppressed, particularly in those taking high dose steroids 
and/or biologic therapies, antivirals should be initiated if vesicles or active lesions are present, 
regardless of time since onset [84, 85].  Treatment should be continued for at least 7 days and until 
all lesions have crusted over and no new lesions have appeared for 48 hours.  
 
Conclusion  
Varicella zoster virus infection is common. Most, but not all, people in the United Kingdom are 
exposed to the virus in childhood. For those who are not and who subsequently commence 
immunosuppressive therapy, rheumatologists need to be aware of the risk of severe de novo 
infection and the indications for VZIG following a significant contact.  Ideally, non-immune patients 
should receive the chickenpox vaccine prior to starting immuosuppressive therapy. Available 
evidence suggests the higher potency shingles vaccine is largely safe in all but the severely 
immunosuppressed. However, uncertainty remains about how exactly to define this group and the 
necessity of establishing serostatus prior to administration. If effective, an inactivate vaccine will 
make these concerns less relevant [72, 75]. Immunosuppressed patients who develop 
uncomplicated shingles should be treated with oral antiviral therapy. Immunosuppressed patients 
with chickenpox or disseminated, multidermal or ophthalmic zoster should be admitted for IV 
antiviral therapy with appropriate infection control measures.  
 Mrs L should be tested for VZV IgG to establish whether she has immunity as despite her history of 
chickenpox she falls into the high risk PHE group B. She tests negative and should therefore be 
offered VZIG. She should be advised to watch for a vesicular rash and antivirals started promptly if 
one develops.  The live varicella vaccine for post exposure prophylaxis would be contraindicated 
given her degree of immunosuppression. If she has other children who have not had chickenpox 
they should be considered for the live varicella vaccine.  Should an inactivated VZV vaccine become 
available she would be a good candidate to receive it once the protective effects of VZIG have worn 
off.   
 
Future research questions and outstanding controversy 
A number of outstanding questions remain including: What is the effect of different 
immunosuppressive medications on VZV specific cell mediated and humoral immunity over time? 
Can we better define which patients will benefit most from serological testing and prophylaxis 
following contact with VZV?  Is VZIG more or less effective than aciclovir as post exposure 
prophylaxis and when should they be combined? Who should have their immunosuppressive 
treatment delayed to allow vaccination?  Is delaying low risk immunosuppression necessary in the 
context of receiving the live chickenpox vaccine and does it affect the likelihood of seroconversion? 
Which patients should have their serostatus checked prior to receiving the higher dose live shingles 
vaccine? If an inactivated vaccine becomes available, who should receive it? Should it be included as 
part of post-exposure prophylaxis and what is the optimum timing of administration?  
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Figure 1. Varicella Zoster Virus life cycle 
Adapted by permission from Macmillan Publishers Ltd, Nature Reviews Microbiology, Zerboni L et 
al., Molecular mechanisms of varicella zoster virus pathogenesis, 12, 197–210. Copyright 2014.  
 
Figure 2. Algorithm for approach following reported contact with Varicella Zoster Virus in an 
immunosuppressed patient 
Derived from PHE guidance for issuing VZIG (Oct 2016). 
 
  
Table 1. Estimated rate of zoster patients with various risk factors, by age group 
Key risk factors of 
interest 
Rate of zoster/1000 person years (99% CI) 
<50 years 50-59 years 60-69 years ≥70 years 
General population 
(2010) 
2.08 (1.74 to 2.49)  4.37 (3.72 to 5.12) 6.69 (5.76 to 7.76) 8.84 (7.49 to 10.43) 
Rheumatoid arthritis 3.51 (2.40 to 5.13) 6.35 (3.46 to 11.66) 9.96 (5.57 to 17.77) 12.47 (6.94 to 22.41) 
Systemic lupus 
erythematosus 
6.32 (3.73 to 10.74) 8.67 (3.2 to 23.46) 8.20 (2.99 to 22.45) 11.36 (4.22 to 30.60) 
Inflammatory bowel 
disease 
3.59 (2.56 to 5.04) 6.13 (3.55 to 10.58) 8.67 (5.10 to 14.74) 10.41 (6.10 to 17.74) 
Chronic obstructive 
pulmonary disease 
2.31 (1.40 to 3.84) 5.62 (2.44 to 12.94) 9.19 (4.09 to 20.62) 11.54 (5.08 to 26.20) 
Asthma 2.58 (2.03 to 3.28) 5.20 (3.81 to 7.11) 8.16 (6.04 to 11.00) 10.44 (7.64 to 14.25) 
Chronic Kidney 
disease 
3.39 (2.38 to 4.85) 5.51 (3.17 to 9.59) 7.60 (4.52 to 12.78) 9.70 (5.74 to 16.37) 
Depression 2.59 (2.03 to 3.31) 4.89 (3.51 to 6.80) 7.22 (5.19 to 10.05) 9.71 (6.94 to 13.58) 
Diabetes 2.66 (1.99 to 3.56) 4.84 (3.23 to 7.27) 6.79 (4.62 to 9.97) 8.55 (5.76 to 12.70) 
  Type 1 3.14 (2.14 to 4.67) 5.08 (2.32 to 11.16) 6.55 (2.66 to 16.12) 5.49 (1.75 to 17.21) 
  Type 2 2.54 (1.84 to 3.54) 4.77 (2.93 to 7.78) 6.79 (4.25 to 10.84) 8.54 (5.28 to 13.79) 
Reproduced from Forbes HJ et al. Quantification of risk factors for herpes zoster: population based 
case-control study. BMJ 2014; 348:g2911 
 
Table 2. Immunosuppressive risk of Varicella Zoster Virus infection with different medications, 
inferred from guidance from Public Health England 
Low Risk Intermediate Risk (PHE group A) High Risk (PHE group B) 
Prednisolone, 
methotrexate or 
azathioprine at doses 
lower than in group A 
Sulfasalazine 
hydroxychloroquine 
 
Any of following in last 3 months: 
Prednisolone >40mg per day for > 
1 week OR >20mg per day for >2 
weeks 
Methotrexate >25mg/week 
Azathioprine >3mg/kg/day 
Mercaptopurine 1.5mg/kg/day 
Any of following in last 6 months: 
Cyclophosphamide 
Biologics 
Cyclosporin 
Leflunomide 
Adapted from Guidance for issuing Varicella Zoster Immunoglobulin [40].  
 
